EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a point-of-care field test for Tasmanian devil facial tumour disease

Anuk Kruawan iD, Rajendra Kc, David A Gell, Jocelyn M Darby, Weizhen Zhu, Chrissie E B Ong iD, Kirsten A Fairfax iD, Andy Flies iD

Royal Society Open Science · 04.11.2026 · 13 (11)

DOI: 10.1098/rsos.260028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Royal Society Open Science, online erschienen am 11.11.2026. Verfasst von Anuk Kruawan und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Health and Medicine, University of Tasmania Menzies Institute for Medical Research, Hobart, Australia. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ARC, Animal Control Technologies Australia, Department of Natural Resources and the Environment Tasmania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Tasmanian devil (Sarcophilus harrisii) population has undergone a major decline in the wild owing to the epidemics of two transmissible cancers known as devil facial tumour 1 (DFT1) and devil facial tumour 2 (DFT2). Understanding the distribution and prevalence of DFT1 and DFT2 is challenging as they can only be detected in field conditions when tumours are large enough to be visually observed. This impedes our ability to understand how the devil population is evolving in response to the tumours. PCR-based diagnostics are available, but the technique is not field-applicable. To overcome these hurdles, we developed an ultrasensitive and field-deployable rapid diagnostic tool. We used a technique called specific high-sensitivity enzymatic reporter unlocking (SHERLOCK), which combines an isothermal nucleic acid amplification step with CRISPR-based recognition and activation of reporter probes to indicate target sequence detection. This system requires only portable laboratory equipment, making it more amenable to field conditions. The results showed that our test can detect DFT1 and DFT2 DNA within the attomolar range. We then confirmed that the test can detect DFT1 in the field using non-invasive swab samples. The SHERLOCK test can be used for more active monitoring and management approaches that are not currently possible.

Schlagwörter

Stichwörter der Autor:innen

CRISPRDFT1DFT2DFTDRPASHERLOCKTasmanian devildiagnosticsisothermal amplificationtransmissible cancer

Autor:innen und Institutionen

  • College of Health and Medicine, University of Tasmania Menzies Institute for Medical Research, Hobart, Australia.
  • Tasmanian School of Medicine, University of Tasmania, Hobart, Australia.

ORCID-Profile: Anuk Kruawan, Chrissie E B Ong, Kirsten A Fairfax, Andy Flies

Förderung

  • ARC
  • Animal Control Technologies Australia
  • Department of Natural Resources and the Environment Tasmania
  • Tasmanian Nature Conservation Fund
  • Ceva Wildlife Research Fund
  • Select Foundation Senior Research Fellowship
  • Menzies Institute for Medical Research
  • Tasmanian Devil Research Grant

Zitieren

APA

Kruawan, A., Kc, R., Gell, D. A., Darby, J. M., Zhu, W., Ong, C. E. B., Fairfax, K. A., & Flies, A. (2026). Development of a point-of-care field test for Tasmanian devil facial tumour disease. Royal Society Open Science, 13(11). https://doi.org/10.1098/rsos.260028

Vancouver

Kruawan A, Kc R, Gell DA, Darby JM, Zhu W, Ong CEB, et al. Development of a point-of-care field test for Tasmanian devil facial tumour disease. Royal Society Open Science. 2026;13(11). doi:10.1098/rsos.260028

BibTeX
@article{Kruawan2026,
  author = {Kruawan, Anuk and Kc, Rajendra and Gell, David A and Darby, Jocelyn M and Zhu, Weizhen and Ong, Chrissie E B and Fairfax, Kirsten A and Flies, Andy},
  title = {Development of a point-of-care field test for Tasmanian devil facial tumour disease},
  journal = {Royal Society Open Science},
  year = {2026},
  volume = {13},
  number = {11},
  doi = {10.1098/rsos.260028}
}
Kostenlos starten →